Clinical trial
Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients…
NCT00399269 · Cadila Pharnmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00399269 |
|---|---|
| Title | Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients With Anemia of Chronic Renal Failure |
| Official title | Assessment of Efficacy & Safety of Recombinant Human Erythropoietin -Alpha, (rHu-EPO-Alpha) in Patients With Anemia of Chronic Renal Failure. |
| Lead sponsor | Cadila Pharnmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anemia |
| Intervention type | Drug |
| Interventions | Recombinant Human Erythropoietin alpha |
| Enrollment | 100 |
| Start date | Dec 1, 2006 |
| Completion | Jun 1, 2007 |
| First posted | Nov 14, 2006 |
| Last update posted | Jun 11, 2009 |
| Countries | India |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: